Index60 Is Superior to HbA1c for Identifying Individuals at High Risk for Type 1 Diabetes.
HbA1c
Index60
metabolic
prevention
type 1 diabetes
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
28 09 2022
28 09 2022
Historique:
received:
11
11
2021
pubmed:
27
7
2022
medline:
30
9
2022
entrez:
26
7
2022
Statut:
ppublish
Résumé
HbA1c from ≥ 5.7% to < 6.5% (39-46 mmol/mol) indicates prediabetes according to American Diabetes Association guidelines, yet its identification of prediabetes specific for type 1 diabetes has not been assessed. A composite glucose and C-peptide measure, Index60, identifies individuals at high risk for type 1 diabetes. We compared Index60 and HbA1c thresholds as markers for type 1 diabetes risk. TrialNet Pathway to Prevention study participants with ≥ 2 autoantibodies (GADA, IAA, IA-2A, or ZnT8A) who had oral glucose tolerance tests and HbA1c measurements underwent 1) predictive time-dependent modeling of type 1 diabetes risk (n = 2776); and 2) baseline comparisons between high-risk mutually exclusive groups: Index60 ≥ 2.04 (n = 268) vs HbA1c ≥ 5.7% (n = 268). The Index60 ≥ 2.04 threshold was commensurate in ordinal ranking with the standard prediabetes threshold of HbA1c ≥ 5.7%. In mutually exclusive groups, individuals exceeding Index60 ≥ 2.04 had a higher cumulative incidence of type 1 diabetes than those exceeding HbA1c ≥ 5.7% (P < 0.0001). Appreciably more individuals with Index60 ≥ 2.04 were at stage 2, and among those at stage 2, the cumulative incidence was higher for those with Index60 ≥ 2.04 (P = 0.02). Those with Index60 ≥ 2.04 were younger, with lower BMI, greater autoantibody number, and lower C-peptide than those with HbA1c ≥ 5.7% (P < 0.0001 for all comparisons). Individuals with Index60 ≥ 2.04 are at greater risk for type 1 diabetes with features more characteristic of the disorder than those with HbA1c ≥ 5.7%. Index60 ≥ 2.04 is superior to the standard HbA1c ≥ 5.7% threshold for identifying prediabetes in autoantibody-positive individuals. These findings appear to justify using Index60 ≥ 2.04 as a prediabetes criterion in this population.
Identifiants
pubmed: 35880956
pii: 6650147
doi: 10.1210/clinem/dgac440
pmc: PMC9516117
doi:
Substances chimiques
Autoantibodies
0
Blood Glucose
0
C-Peptide
0
Glycated Hemoglobin A
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2784-2792Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK107014
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085476
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085466
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106993
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103282
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061058
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK107013
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061034
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103180
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061042
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106984
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085453
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085499
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061010
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085465
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106994
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103153
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085504
Pays : United States
Organisme : NIDDK NIH HHS
ID : UC4 DK106993
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103266
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085461
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085509
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Diabetes Care. 2022 Feb 1;45(2):311-318
pubmed: 34853027
Diabetes Care. 2012 Jun;35(6):1213-8
pubmed: 22446173
J Clin Endocrinol Metab. 2010 Jul;95(7):3360-7
pubmed: 20444913
Diabetologia. 2021 Apr;64(4):836-844
pubmed: 33496819
Diabetes Care. 2017 Nov;40(11):1494-1499
pubmed: 28860125
Pediatr Diabetes. 2009 Apr;10(2):97-104
pubmed: 18823409
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
Diabetologia. 2020 Mar;63(3):588-596
pubmed: 31768570
Diabetes Care. 2015 Oct;38(10):1964-74
pubmed: 26404926
Pediatr Diabetes. 2016 Jul;17 Suppl 22:25-30
pubmed: 27411433
JCI Insight. 2018 Aug 9;3(15):
pubmed: 30089716
Diabetes Care. 2010 Mar;33(3):620-5
pubmed: 20032282
Pediatr Diabetes. 2019 May;20(3):263-270
pubmed: 30628751
Diabetes Care. 2012 Sep;35(9):1821-5
pubmed: 22699293
Diabetes Care. 2015 Feb;38(2):271-6
pubmed: 25519451